156th WHO Executive Board (EB156): Individual statement on non-communicable diseases
On 5 February at the EB156 in Geneva, IFPMA delivered a statement on non-communicable diseases (NCDs).
IFPMA welcomes the EB156 report on NCDs and WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes. With childhood obesity and diabetes on an alarming rise, alongside ageing, urbanization, climate change, air pollution amongst other factors, a life-course approach to tackling NCDs is critical given the unsustainable pressures chronic conditions and co-morbidities are placing on healthcare systems worldwide.
Progress is lacking amongst many countries in the world on prevention and control of NCDs. We must come together and redouble efforts to bend the curve. Ahead of the 4th United Nations High Level meeting on NCDs, we urge Member States to embrace innovation, mobilize investment, drive implementation, and ensure accountability. Our industry remains a committed stakeholder in tackling NCDs and will continue working with others to build access solutions and contribute toward stronger health systems to improve the lives of people living with NCDs.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
